Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Meta Expands AI Training With Employee Activity Tracking Tools 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
MENLO PARK, Calif., March 28, 2017 -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it will present at the Needham & Company 16th Annual Healthcare Conference. Andrew Guggenhime, chief operating officer and chief financial officer of Dermira, is scheduled to present at 2:20 p.m. ET (11:20 a.m. PT) on Tuesday, April 4, 2017, in New York. A live audio webcast and replay of the presentation will be available on the Investors section of Dermira’s corporate website at www.dermira.com.
About Dermira
Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify and develop leading-edge medical dermatology programs. Dermira’s product pipeline includes three Phase 3 product candidates that could have a profound impact on the lives of patients: glycopyrronium tosylate (formerly DRM04), in development for the treatment of primary axillary hyperhidrosis (excessive underarm sweating); CIMZIA® (certolizumab pegol), in development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe chronic plaque psoriasis; and olumacostat glasaretil (formerly DRM01), in development for the treatment of acne vulgaris. Dermira is headquartered in Menlo Park, Calif. For more information, please visit www.dermira.com.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Dermira uses its website (www.dermira.com) and LinkedIn page (https://www.linkedin.com/company/dermira-inc-) as channels of distribution of information about its company, product candidates, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Dermira’s website and LinkedIn page in addition to following its SEC filings, press releases, public conference calls and webcasts.
Contacts: Media: Erica Jefferson Senior Director, Head of Corporate Communications 650-421-7216 [email protected] Investors: Andrew Guggenhime Chief Operating Officer and Chief Financial Officer 650-421-7200 [email protected] Robert H. Uhl Westwicke Partners Managing Director 858-356-5932 [email protected]
